David A Cox

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Randomized Controlled Trial

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Petter Bjornstad, Silva A Arslanian, Tamara S Hannon, Philip S Zeitler, Jennie L Francis, Alexandra M Curtis, Ibrahim Turfanda, David A Cox
Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes care (2024)
Petter Bjornstad, Silva A Arslanian, Tamara S Hannon, Philip S Zeitler, Jennie L Francis, Alexandra M Curtis, Ibrahim Turfanda, David A Cox
Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes care 47 (9) (2024)
David A Cox, Hui Wang, Claudia Nicolay, Mary Angelyn Bethel
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study. Diabetes, obesity & metabolism 24 (9) (2022)
Juan Pablo Frias, Enzo Bonora, Luis Nevarez Ruiz, Ying G Li, Zhuoxin Yu, Zvonko Milicevic, Raleigh Malik, M Angelyn Bethel, David A Cox
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes care 44 (3) (2021)
Juan Pablo Frias, Enzo Bonora, David A Cox, M Angelyn Bethel, Anita Y M Kwan, Sohini Raha, Raleigh E Malik
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11. Diabetes, obesity & metabolism 23 (12) (2021)
Juan Pablo Frias, Enzo Bonora, Luis Nevárez Ruiz, Stanley H Hsia, Heike Jung, Sohini Raha, David A Cox, M Angelyn Bethel, Manige Konig
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial. Diabetes, obesity & metabolism 23 (10) (2021)
Enzo Bonora, Juan P Frias, Francisco J Tinahones, Joanna Van, Raleigh E Malik, Zhuoxin Yu, Reema Mody, Angelyn Bethel, Anita Y M Kwan, David A Cox
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes, obesity & metabolism 23 (10) (2021)